Last Updated: November 8, 2026

Patent: 7,374,756

Summary for Patent: 7,374,756

Title:	Specific binding agents for KSHV vIL-6 that neutralize a biological activity
Abstract:	A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.
Inventor(s):	Yoshiyasu Aoki, Giovanna Tosato
Assignee:	US Department of Health and Human Services
Application Number:	US11/803,732
Patent Claims:	see list of patent claims

Details for Patent 7,374,756

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi Vaccines Canada Ltd.	TENIVAC	tetanus and diphtheria toxoids adsorbed	Injection	103171	November 3, 2003	⤷ Start Trial	2027-05-14
Bavarian Nordic A/s	VAXCHORA	cholera vaccine, live, oral	Suspension	125597	June 10, 2016	⤷ Start Trial	2027-05-14
Bavarian Nordic A/s	VAXCHORA	cholera vaccine, live, oral	Suspension	125597	December 23, 2020	⤷ Start Trial	2027-05-14
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,374,756

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	7812901	⤷ Start Trial
United States of America	2003211468	⤷ Start Trial
United States of America	2006039927	⤷ Start Trial
United States of America	2007015197	⤷ Start Trial
United States of America	2007243162	⤷ Start Trial
United States of America	2008260687	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.